RIVASTIGMINE ARROW 4.5 mg, hard capsule 28 capsules
Active ingredients: Rivastigmine tartrate, Rivastigmine
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule28 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RIVASTIGMINE ARROW 4,5 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène PVDC aluminium de 28 gélule(s)
- Marketing authorisation holder
- ARROW GENERIQUES
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 15 Mar 2016
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a specialist
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61647575CIP72685025CIP133400926850258Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RIVASTIGMINEgélule | 4,5 mg · une gélule | FT |
| HYDROGÉNOTARTRATE DE RIVASTIGMINEgélule | 7,2 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.